Effect of Traditional Therapeutics on Prevalence and Clinical Outcomes of Coronavirus Disease 2019 in Chinese Patients with Autoimmune Diseases

Overview

Journal J Transl Autoimmun

Date 2024 Jan 8

PMID 38188040

Authors

Saisai Huang

Xiaolei Ma

Juan Cao

Mengru Du

Zhiling Zhao

Dandan Wang

Xue Xu

Jun Liang

Lingyun Sun

Affiliations

Soon will be listed here.

Abstract

The impact of the Coronavirus disease 2019 (COVID-19) pandemic on autoimmune diseases (AID) patients has been an important focus. This study was undertaken to characterize the incidence, clinical manifestations and hospitalization among AID affected by COVID-19 and to analyze the association between immunomodulatory medication and these outcomes. Clinical, demographic, maintenance treatment, symptoms and disease course data and outcomes of AID patients with COVID-19 infection were assessed via an online survey tool and printed copy from 1 January till February 28, 2023. A total of 432 patients with AID were enrolled in the study. The results showed the most common conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was hydroxychloroquine (HCQ). The usage of csDMARDs didn't increase the risk of COVID-19 infection. Patients who warranted hospitalization were significantly older. ILD was associated with higher hospitalization rate. No csDMARDs other than calcineurin inhibitor (CNI) was associated with increased risk of hospitalization. HCQ intake was associated with cough. Compared with no glucocorticoids (GCs) group, high doses of GCs were accompanied with higher proportion of gastrointestinal symptoms and tachycardia, lower proportion of sore throat and ageusia. GCs didn't provoke the COVID-19 infection in patients with AID, but chronic use of oral GCs was significantly more common in those requiring hospitalization, and higher dose of GCs were correlated with higher risk of hospitalization. 97 patients discontinued csDMARDs after infection, which resulted in an elevated risk of hospitalization. Meanwhile, withdrawal of csDMARDs was associated with higher odds of disease flare and lower proportion of remission than maintenance groups. Collectively, our analysis provides the evidence that maintenance treatment of csDMARDs may be more prudent for AID patients during COVID-19 pandemic.

References

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Schultze A, Walker A, Mackenna B, Morton C, Bhaskaran K, Brown J . Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8(11):1106-1120. PMC: 7515601. DOI: 10.1016/S2213-2600(20)30415-X. View

Muralidar S, Ambi S, Sekaran S, Krishnan U . The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020; 179:85-100. PMC: 7505773. DOI: 10.1016/j.biochi.2020.09.018. View

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A . Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223):e30-e31. PMC: 7137985. DOI: 10.1016/S0140-6736(20)30304-4. View

Russell B, Moss C, Rigg A, Van Hemelrijck M . COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience. 2020; 14:1023. PMC: 7105332. DOI: 10.3332/ecancer.2020.1023. View

Bedford J, Enria D, Giesecke J, Heymann D, Ihekweazu C, Kobinger G . COVID-19: towards controlling of a pandemic. Lancet. 2020; 395(10229):1015-1018. PMC: 7270596. DOI: 10.1016/S0140-6736(20)30673-5. View

Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020; 324(13):1330-1341. PMC: 7489434. DOI: 10.1001/jama.2020.17023. View

Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin J, Sutton S . Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med. 2020; 1(1):114-127.e3. PMC: 7274588. DOI: 10.1016/j.medj.2020.06.001. View

Akiyama S, Hamdeh S, Micic D, Sakuraba A . Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020; 80(3):384-391. DOI: 10.1136/annrheumdis-2020-218946. View

10.

Christen U . Pathogen infection and autoimmune disease. Clin Exp Immunol. 2018; 195(1):10-14. PMC: 6300646. DOI: 10.1111/cei.13239. View

11.

Sepriano A, Kerschbaumer A, Smolen J, van der Heijde D, Dougados M, van Vollenhoven R . Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020; 79(6):760-770. DOI: 10.1136/annrheumdis-2019-216653. View

12.

Ozuygur Ermis S, Ergan B, Kacmaz Basoglu O, Ercan S, Korkmaz Ekren P, Kuruuzum Z . The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on Hospital Mortality in COVID 19 Pneumonia Patients. Turk J Med Sci. 2021; . DOI: 10.3906/sag-2009-64. View

13.

Burrage D, Koushesh S, Sofat N . Immunomodulatory Drugs in the Management of SARS-CoV-2. Front Immunol. 2020; 11:1844. PMC: 7438578. DOI: 10.3389/fimmu.2020.01844. View

14.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

15.

Peters M, Sajuthi S, DeFord P, Christenson S, Rios C, Montgomery M . COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020; 202(1):83-90. PMC: 7328313. DOI: 10.1164/rccm.202003-0821OC. View

16.

Shin Y, Shin J, Moon S, Jin H, Kim S, Yang J . Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021; 3(10):e698-e706. PMC: 8213376. DOI: 10.1016/S2665-9913(21)00151-X. View

17.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

18.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

19.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

20.

Haberman R, Castillo R, Chen A, Yan D, Ramirez D, Sekar V . COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 2020; 72(12):1981-1989. PMC: 7722024. DOI: 10.1002/art.41456. View